{"id":"NCT00492063","sponsor":"Novartis Vaccines","briefTitle":"Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly","officialTitle":"A Phase III, Observer-Blind, Randomized, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture and of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs, in Healthy Adult and Elderly Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-09","primaryCompletion":"2004-12","completion":"2005-05","firstPosted":"2007-06-27","resultsPosted":"2013-02-21","lastUpdate":"2016-01-01"},"enrollment":2654,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Cell culture-derived trivalent subunit influenza vaccine (cTIV)","otherNames":[]},{"type":"BIOLOGICAL","name":"Egg-derived trivalent subunit influenza vaccine (TIV)","otherNames":[]}],"arms":[{"label":"Cell culture-derived influenza vaccine (cTIV)","type":"EXPERIMENTAL"},{"label":"Egg-derived influenza virus vaccine (TIV)","type":"ACTIVE_COMPARATOR"}],"summary":"The present study aims to evaluate the safety and immunogenicity of the new influenza subunit vaccine produced in Madin Darby Canine Kidney (MDCK) cells in healthy adult and elderly subjects.","primaryOutcome":{"measure":"Percentages Of Subjects Who Achieved HI Titer â‰¥40 After One Vaccination of Cell Culture-derived (cTIV) or Egg-derived (TIV) Influenza Subunit Vaccines","timeFrame":"Before vaccination (day 1) and three weeks after vaccination (day 22)","effectByArm":[{"arm":"cTIV (Adults)","deltaMin":29,"sd":null},{"arm":"TIV (Adults)","deltaMin":33,"sd":null},{"arm":"cTIV (Elderly)","deltaMin":30,"sd":null},{"arm":"TIV (Elderly)","deltaMin":31,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["Poland"]},"refs":{"pmids":["19673651"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":652},"commonTop":["Injection site pain","Injection site erythema","Headache","Fatigue","Malaise"]}}